By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
A Deep Pipeline of Allogeneic, Off-The-Shelf, Virus-Specific T Cell (VST) Therapies
A large number of patients are fighting viral infections or diseases with limited or no treatment options. To address this, we are advancing a pipeline of allogeneic, off-the-shelf VSTs to treat or prevent life-threatening viral diseases.
Multi-VSTs targeting Human Metapneumovirus (hMPV), Influenza (Flu), Parainfluenza Virus (PIV), and Respiratory syncytial virus (RSV). *High-risk general population: immunocompromised cancer patients, the elderly, and very young.
Allo-HSCT: allogeneic HSCT; Auto-HSCT: autologous HSCT; POC: Proof-of-concept; High-risk general population: immunocompromised cancer patients, the elderly, and very young.
Our allogeneic, off-the-shelf VST candidates benefit patients with T cell deficiencies, including transplant recipients, immunocompromised cancer patients, the elderly, and the very young, who are at a higher risk of the devastating consequences of viral diseases.
AlloVir is the global leader in developing VST immunotherapies
We develop highly innovative, allogeneic, off-the-shelf, virus-specific T cell (VST) therapies designed to prevent and treat life-threatening viral diseases.
Our Pipeline
Our allogeneic, off-the-shelf VST therapy candidates target 12 different devastating viruses as treatment or prevention.
AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?
AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?
